MedTrace Logo

Adult Subjects With Uncontrolled Type 2 Diabetes

NCT02317796 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2016-09-26

No results posted yet for this study

Summary

A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes

Conditions

Interventions

DRUG

MLR-1023

Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.

Sponsors & Collaborators

  • Bukwang Pharmaceutical, Co., Ltd.

    collaborator INDUSTRY

  • Melior Pharmaceuticals

    lead OTHER

Principal Investigators

  • Melior Pharmaceuticals I & Bukwang Pharm. Co., Ltd. · Melior Pharmaceuticals I & Bukwang Pharm. Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-12-31
Completion
2016-02-29

Countries

  • United States

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02317796 on ClinicalTrials.gov